NEW YORK (GenomeWeb) – Fluidigm this week announced the sale of 9,090,909 shares of common stock, which it expects will raise gross proceeds of roughly $30 million before commissions and offering costs.

The company sold the shares through its "at-the-market" equity offering program, which it announced earlier this month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.